Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hightide Therapeutics Inc ( (HK:2511) ) has shared an update.
HighTide Therapeutics reported its audited consolidated annual results for the year ended December 31, 2025, and detailed a change in the use of proceeds, underscoring its continued focus on advancing HTD1801 as its core asset. The company highlighted robust clinical proof-of-concept data showing that HTD1801 delivers multifaceted metabolic benefits, including improved glycemic control, lipid lowering, renal and liver function improvements, weight reduction, and reductions in systemic inflammation markers.
Management emphasized that CKM-related diseases represent a major unmet medical need, affecting the vast majority of adults in markets such as the U.S. and China, and noted that current therapies leave substantial residual risk due to limited impact on chronic inflammation and incomplete control of metabolic and cardiorenal complications. By targeting both metabolic dysregulation and inflammation, HighTide believes HTD1801 could become a foundational CKM therapy and a broad-spectrum metabolic regulator, with potential for use as monotherapy or in combination with existing treatments, positioning the company to address a large and underserved global market.
The most recent analyst rating on (HK:2511) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Hightide Therapeutics Inc stock, see the HK:2511 Stock Forecast page.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing transformative therapeutic solutions for cardiovascular-kidney-metabolic diseases, or CKM. Its lead product candidate, HTD1801, is a first-in-class, orally delivered anti-inflammatory metabolic modulator designed to address residual risks in complex CKM-related conditions through a dual mechanism of AMPK activation and NLRP3 inflammasome inhibition.
Average Trading Volume: 821,538
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.49B
See more data about 2511 stock on TipRanks’ Stock Analysis page.